



BARCLAYS BANK PLC

(Incorporated with limited liability in England and Wales)

This supplement dated 3 October 2022 (the "**Supplement**") constitutes a supplement for the purposes of Articles 10(1) and 23(5) of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 as it forms part of domestic law of the United Kingdom by virtue of the European Union (Withdrawal) Act 2018, as amended (the "**UK Prospectus Regulation**").

This Supplement is supplemental to and must be read in conjunction with the registration document 9/2022 dated 7 March 2022, as supplemented by Supplement 1/2022 dated 30 March 2022, Supplement 2/2022 dated 24 May 2022 and Supplement 3/2022 dated 11 August 2022 (together, the "**Registration Document**") prepared for the purposes of giving information with respect to Barclays Bank PLC (the "**Issuer**").

This Supplement supplements the Registration Document, and as a consequence of this, each of the following multipartite base prospectuses (constituted by the Registration Document and a securities note dated the approval date of the respective base prospectus) will be updated: the Issuer's (i) Global Structured Securities Programme Base Prospectus 16 approved on 1 July 2022 (the "**GSSP Base Prospectus 16**"), (ii) Global Structured Securities Programme Base Prospectus 1A approved on 22 August 2022 and (iii) Global Structured Securities Programme Base Prospectus 2 approved on 23 August 2022 (the "**GSSP Base Prospectus 2**").

This Supplement has been approved by the United Kingdom Financial Conduct Authority (the "**FCA**"), as competent authority under the UK Prospectus Regulation. The FCA only approves this Supplement as meeting the standards of completeness, comprehensibility and consistency imposed by the UK Prospectus Regulation. Such approval should not be considered as an endorsement of the Issuer that is the subject of this Supplement. With effect from the date of this Supplement the information appearing in, or incorporated by reference into, the Registration Document shall be supplemented in the manner described below.

Terms defined in the Registration Document shall, unless the context otherwise requires, have the same meaning when used in this Supplement.

In accordance with Article 23(2) of the UK Prospectus Regulation, investors who have already agreed to purchase or subscribe for securities pursuant to the GSSP Base Prospectus 16 or the GSSP Base Prospectus 2 before this Supplement is published have the right, exercisable within two working days after the publication of this Supplement, to withdraw their acceptances, and should contact the relevant distributor of such securities in connection therewith. The final date of the right of withdrawal will be 5 October 2022.

The purpose of this Supplement is to supplement the section entitled "*Information Incorporated by Reference*" commencing on page 22 of the Registration Document and incorporate by reference into the Registration Document the RNS Announcement of the Issuer and Barclays PLC, as filed with the SEC on Form 6-K on 30 September 2022, in respect of an update on over-issuance under the Issuer's U.S. Shelf (the "**Over-Issuance Update Announcement**"). The Over-Issuance Update Announcement has been filed with the FCA and shall be deemed to be incorporated in, and form part of, the Registration Document as supplemented by this Supplement. The Over-Issuance Update Announcement may be inspected during normal business hours at Barclays Treasury, 1 Churchill Place, London, E14 5HP, United Kingdom and at the specified office of the Principal Paying Agent, at One Canada Square, London, E14 5AL, United Kingdom during the life of the Registration Document. It has also been filed with the SEC and is available in electronic form on the SEC's website at https://www.sec.gov/Archives/edgar/data/312070/000114036122035483/brhc10042524_6k.htm.

References to the Registration Document shall hereafter mean the Registration Document as supplemented by this Supplement. The Issuer accepts responsibility for the information contained in this Supplement and declares that, to the best of its knowledge, the information contained in this Supplement is in accordance with the facts and that this Supplement makes no omission likely to affect its import. To the extent that there is any inconsistency between (a) any statement in this supplement or any statement incorporated by reference into the Registration Document by this supplement and (b) any other statement in, or incorporated by reference in, the Registration Document, the statements in (a) above will prevail.

If documents which are incorporated by reference into this Supplement themselves incorporate any information or other documents therein, either expressly or implicitly, such information or other documents will not form part of this Supplement for the purposes of the UK Prospectus Regulation except where such information or other documents are specifically incorporated by reference into this Supplement. Save as disclosed in this Supplement, there has been no other significant new factor, material mistake or material inaccuracy relating to information included in the Registration Document since the publication of the Registration Document.

The date of this Supplement is 3 October 2022